Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
Late-onset Pompe disease (LOPD) is an autosomal recessive disorder caused by deficiency of the enzyme acid glucosidase alfa (GAA). Recently, enzyme replacement therapy (ERT) using recombinant human GAA (rhGAA) became clinically available, and is expected to modify the clinical course in LOPD of various stages. In this study, we evaluated the efficacy and adverse events of ERT for 48 weeks in Korean LOPD patients. Five Korean LOPD patients were included in the study. At baseline, clinical and laboratory features, including muscular and pulmonary function, were assessed, and rhGAA was infused every 2 weeks. Then, patients were examined at every 12-week interval for evaluation of changes in motor and pulmonary function for 48 weeks along with adverse reactions to ERT. The muscular and pulmonary function of the patients varied depending on the baseline condition of the patient after 48 weeks of ERT. However, the overall function of the patients showed stabilization of the disease rather than the improvement seen in infantile-onset Pompe disease. This is the first clinical study on ERT of Korean LOPD patients. Results of our study showed stabilization of muscular and pulmonary function in LOPD patients for 48 weeks with a favorable prognosis for patients who received early diagnosis and ambulatory patients. One of our patients developed a serious anaphylactic reaction, which necessitated the cessation of further ERT. Therefore, our study shows that early diagnosis and ERT are important in preventing further deterioration of the disease.
Department of Neurology, Kyungpook National University School of Medicine, Daegu, Korea.
Jin-Sung
JS
Park
Hye-Gyung
HG
Kim
Jin-Hong
JH
Shin
Young-Chul
YC
Choi
Dae-Seong
DS
Kim
D000328:Adult; D001786:Blood Glucose; D002648:Child; D003402:Creatine Kinase / Q000097:blood; D056947:Enzyme Replacement Therapy; D005260:Female; D005500:Follow-Up Studies; D005087:Glucan 1,4-alpha-Glucosidase / Q000627:therapeutic use*; D006009:Glycogen Storage Disease Type II / Q000628:therapy*; D006801:Humans; D008297:Male; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D010865:Pilot Projects; D012189:Retrospective Studies
D001786:Blood Glucose; D003402:Creatine Kinase; D005087:Glucan 1,4-alpha-Glucosidase